Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 3

4(66.7%)

N/A

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 3(4)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01244789Phase 2Active Not Recruiting

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

Role: collaborator

NCT04111978Phase 3Recruiting

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

Role: collaborator

NCT01658930Not ApplicableCompleted

Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

Role: collaborator

NCT02477644Phase 3Completed

Platine, Avastin and OLAparib in 1st Line

Role: collaborator

NCT01837251Phase 3Completed

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Role: collaborator

NCT00189553Phase 3Completed

Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse

Role: collaborator

NCT00368420Completed

Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer

Role: collaborator

All 7 trials loaded